Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
129.69
-3.53 (-2.65%)
At close: May 29, 2026, 4:00 PM EDT
128.11
-1.58 (-1.22%)
After-hours: May 29, 2026, 7:58 PM EDT
Guardant Health Revenue
Guardant Health had revenue of $301.67M in the quarter ending March 31, 2026, with 48.26% growth. This brings the company's revenue in the last twelve months to $1.08B, up 39.56% year-over-year. In the year 2025, Guardant Health had annual revenue of $982.02M with 32.88% growth.
Revenue (ttm)
$1.08B
Revenue Growth
+39.56%
P/S Ratio
15.92
Revenue / Employee
$431,051
Employees
2,506
Market Cap
17.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 982.02M | 243.01M | 32.88% |
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
| Dec 31, 2019 | 214.38M | 123.74M | 136.52% |
| Dec 31, 2018 | 90.64M | 40.80M | 81.85% |
| Dec 31, 2017 | 49.84M | 24.59M | 97.40% |
| Dec 31, 2016 | 25.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 16.63B |
| Labcorp Holdings | 14.14B |
| Quest Diagnostics | 11.28B |
| ICON Public Limited Company | 8.25B |
| Agilent Technologies | 7.07B |
| Illumina | 4.39B |
| Mettler-Toledo International | 4.09B |
| Waters | 3.77B |
GH News
- 1 day ago - Guardant Health to present 38 abstracts at ASCO 2026 meeting - TheFly
- 1 day ago - Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting - Business Wire
- 2 days ago - Guardant Health management to meet with Craig-Hallum - TheFly
- 2 days ago - Guardant Health price target raised to $160 from $155 at BTIG - TheFly
- 2 days ago - ACS recommends Guardant Health’s Shield blood test in screening guidelines - TheFly
- 2 days ago - American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines - Business Wire
- 2 days ago - Blood test added to US colorectal cancer screening options - Reuters
- 3 days ago - Guardant Health management to meet with Craig-Hallum - TheFly